XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2017
USD ($)
PerformanceObligation
May 31, 2015
USD ($)
Mar. 31, 2021
USD ($)
PerformanceObligation
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
Agreement
Revenue Recognition [Abstract]                
Number of performance obligations at inception of contract | PerformanceObligation     1          
Revenue     $ 111,607     $ 133,367    
Biogen [Member]                
Revenue Recognition [Abstract]                
Number of agreements | Agreement               2
AstraZeneca [Member] | ION449 [Member]                
Revenue Recognition [Abstract]                
Revenue       $ 20,000        
AstraZeneca [Member] | ION455 [Member]                
Revenue Recognition [Abstract]                
Revenue       30,000        
IONIS-FB-L for Complement-Mediated Diseases [Member]                
Revenue Recognition [Abstract]                
Upfront payment received             $ 75,000  
Biogen 2018 Strategic Neurology [Member]                
Revenue Recognition [Abstract]                
Milestone payment received and added to transaction price       $ 7,500        
Biogen 2013 Strategic Neurology [Member] | ION464 [Member]                
Revenue Recognition [Abstract]                
Revenue         $ 18,000      
Bayer [Member]                
Revenue Recognition [Abstract]                
Upfront payment received   $ 100,000            
Bayer [Member]                
Revenue Recognition [Abstract]                
Upfront payment received $ 75,000              
Number of separate performance obligations | PerformanceObligation 3              
Transaction price $ 75,000